These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 18021410)

  • 1. The prognostic value of the suPARnostic ELISA in HIV-1 infected individuals is not affected by uPAR promoter polymorphisms.
    Schneider UV; Nielsen RL; Pedersen C; Eugen-Olsen J
    BMC Infect Dis; 2007 Nov; 7():134. PubMed ID: 18021410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection.
    Sidenius N; Sier CF; Ullum H; Pedersen BK; Lepri AC; Blasi F; Eugen-Olsen J
    Blood; 2000 Dec; 96(13):4091-5. PubMed ID: 11110678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
    Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa.
    Lawn SD; Myer L; Bangani N; Vogt M; Wood R
    BMC Infect Dis; 2007 May; 7():41. PubMed ID: 17509133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy.
    Ostrowski SR; Katzenstein TL; Pedersen M; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    Scand J Immunol; 2006 Jun; 63(6):478-86. PubMed ID: 16764702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients.
    Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
    J Acquir Immune Defic Syndr; 2005 May; 39(1):23-31. PubMed ID: 15851910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.
    Stephens RW; Nielsen HJ; Christensen IJ; Thorlacius-Ussing O; Sørensen S; Danø K; Brünner N
    J Natl Cancer Inst; 1999 May; 91(10):869-74. PubMed ID: 10340907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: a prospective cohort study.
    Rabna P; Andersen A; Wejse C; Oliveira I; Francisco Gomes V; Bonde Haaland M; Aaby P; Eugen-Olsen J
    Inflammation; 2010 Dec; 33(6):374-80. PubMed ID: 20229356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test.
    Rabna P; Andersen A; Wejse C; Oliveira I; Gomes VF; Haaland MB; Aaby P; Eugen-Olsen J
    Trop Med Int Health; 2009 Sep; 14(9):986-94. PubMed ID: 19725925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 infected lymphoid organs upregulate expression and release of the cleaved form of uPAR that modulates chemotaxis and virus expression.
    Nebuloni M; Zawada L; Ferri A; Tosoni A; Zerbi P; Resnati M; Poli G; Genovese L; Alfano M
    PLoS One; 2013; 8(7):e70606. PubMed ID: 23923008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble urokinase receptor levels in plasma during 5 years of highly active antiretroviral therapy in HIV-1-infected patients.
    Ostrowski SR; Katzenstein TL; Piironen T; Gerstoft J; Pedersen BK; Ullum H
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):337-42. PubMed ID: 15097149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations.
    Cinque P; Nebuloni M; Santovito ML; Price RW; Gisslen M; Hagberg L; Bestetti A; Vago G; Lazzarin A; Blasi F; Sidenius N
    Ann Neurol; 2004 May; 55(5):687-94. PubMed ID: 15122709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients.
    Lomholt AF; Christensen IJ; Høyer-Hansen G; Nielsen HJ
    Acta Oncol; 2010 Aug; 49(6):805-11. PubMed ID: 20524776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients.
    Fernebro E; Madsen RR; Fernö M; Brünner N; Bendahl P; Christensen IJ; Johnson A; Nilbert M
    Eur J Cancer; 2001 Mar; 37(4):486-91. PubMed ID: 11267858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy.
    Andersen O; Eugen-Olsen J; Kofoed K; Iversen J; Haugaard SB
    J Med Virol; 2008 Feb; 80(2):209-16. PubMed ID: 18098145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy.
    Mustjoki S; Sidenius N; Sier CF; Blasi F; Elonen E; Alitalo R; Vaheri A
    Cancer Res; 2000 Dec; 60(24):7126-32. PubMed ID: 11156421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study.
    Jalkanen V; Vaahersalo J; Pettilä V; Kurola J; Varpula T; Tiainen M; Huhtala H; Alaspää A; Hovilehto S; Kiviniemi O; Kuitunen A; Tenhunen J;
    Resuscitation; 2014 Nov; 85(11):1562-7. PubMed ID: 25193800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome.
    Raggam RB; Wagner J; Prüller F; Grisold A; Leitner E; Zollner-Schwetz I; Valentin T; Krause R; Hoenigl M
    J Intern Med; 2014 Dec; 276(6):651-8. PubMed ID: 24645798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia.
    Erkut N; Menteşe A; Özbaş HM; Ermantaş N; Sümer A; Örem A; Sönmez M
    Turk J Haematol; 2016 Jun; 33(2):135-40. PubMed ID: 26376588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.